000 04991cam a2200481Ii 4500
001 96555
003 ES-MaUEC
005 20230102112759.0
006 m d
007 cr |n|---aucuu
008 170930s2017 sz ob 001 0 eng d
020 _a3319582445
_q(electronic bk.)
020 _a9783319582443
_q(electronic bk.)
020 _z3319582437
020 _z9783319582436
040 _aEBLCP
_beng
_erda
_cEBLCP
_dGW5XE
_dN$T
_dYDX
_dMERER
_dOCLCF
_dOCLCO
_dIOG
_dCOO
_dOCLCQ
_dES-MaUEC
_bspa
050 4 _aQP601.3
_b2017 EB
245 0 0 _aProtein deimination in human health and disease
_cAnthony P. Nicholas, Sanjoy K. Bhattacharya, Paul R. Thompson, editors.
250 _aSecond edition.
264 1 _aCham, Switzerland
_bSpringer International Publishing
_c2017
264 4 _c2017
300 _a1 recurso en línea
336 _aTexto
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
500 _a7.6 The Associations of PD with Systemic Diseases: A General Concept
500 _a
_bSpringer Biomedical and Life Sciences eBooks 2017 English+International
504 _aIncluye referencias bibliográficas e índice
505 0 _aDedication; Contents; Chapter 1: A History of Deimination Research in Japan: The Founding Fathers; References; Chapter 2: Aspects of Peptidylarginine Deiminase Regulation that May Predispose to Autoreactivity Against Citrullinated Proteins; 2.1 Summary; 2.2 Tolerance and Autoimmunity; 2.3 Discovery of Arginine Deimination; 2.4 Role of PAD4 in Innate Immune Responses; 2.5 PAD4 and NETs; 2.6 NETs in Autoimmunity; 2.7 Model of PAD4 Activation in the Pathogenesis of Autoimmune Disease; References; Chapter 3: Structures and Functions of Peptidylarginine Deiminases; 3.1 Introduction
505 8 _a3.2 PAD Isozymes: Similarities and Differences3.2.1 Overall Folds; 3.2.2 Structures and the Functions of the Catalytic Domains; 3.2.3 Ca2+-Binding Sites and Functions; 3.2.4 Structures and the Functions of N-Terminal Ig-Like Domain; 3.3 Application of PAD Structures for Drug Design; 3.4 Conclusions; References; Chapter 4: The Use of Genetically Engineered Mice to Study PAD Biology and Pathology; 4.1 Introduction; 4.2 PAD2; 4.3 PAD3; 4.4 PAD4; 4.5 PAD6; 4.6 Conclusions; References; Chapter 5: PAD Activation in Arthritis; 5.1 Introduction; 5.2 Methods to Determine PAD Activity
505 8 _a5.3 PAD Substrate Specificity5.4 PAD Isoforms Involved in Arthritis; 5.4.1 PAD2 and PAD4 Expression in Hematopoietic Cells; 5.4.2 PAD2 and PAD4 Expression in Joints; 5.5 PAD Activation; 5.5.1 Calcium; 5.5.2 Reducing Conditions; 5.6 PAD and NETosis; 5.7 PAD Activation and Citrullination in Relation to Inflammation in RA; 5.8 Citrullinated Proteins in Synovial Fluid; 5.9 Concluding Remarks; References; Chapter 6: Rheumatoid Arthritis: Transition from Systemic Autoimmunity to Joint Inflammation and Bone Loss; 6.1 Introduction
505 8 _a6.2 The Immune System Might Be Primed Against Citrullinated Autoantigens at Mucosal Extra-­Articular Sites6.3 Autoimmunity Against Citrullinated Proteins Gradually Develops and Precedes Chronic Joint Inflammation; 6.4 ACPAs Target Maturing Osteoclasts Leading to Bone Loss and Pain in the Absence of Inflammation; 6.5 Summary; References; Chapter 7: Porphyromonas gingivalis Peptidyl Arginine Deiminase: A Unique Bacterial PAD with Implications for Periodontal Disease and Rheumatoid Arthritis; 7.1 Introduction; 7.2 Epidemiology, Etiology, and Clinical Features of PD
505 8 _a7.3 Oral Cavity Colonization and PD7.4 Porphyromonas gingivalis Is a Main Causative Agent of PD in Adult Population; 7.5 Citrullination Is a Posttranslational Modification Catalyzed by Peptidyl Arginine Deiminases; 7.5.1 Citrullination Catalyzed by PAD/PADI Is a Common Physiological Protein Modification; 7.5.2 Citrullination Catalyzed by PAD/PADI Is Implicated in the Pathogenesis of Several Diseases; 7.5.3 Citrullination Catalyzed by PPAD Is a Unique Feature of P. gingivalis; 7.5.4 Biochemical Properties of PPAD; 7.5.5 The Facts and Hypotheses on PPAD Implication in the Pathogenesis of PD
520 3 _aChronicling the earliest studies of deimination in the nervous system up to the present, this volume distills what is currently known about citrullination of proteins in the eye and nervous system.
650 7 _aProteínas
_2embne
_0(OCoLC)fst01079711
_0
_9139861
650 7 _aInmunología
_0(OCoLC)fst00968006
_0
_2embne
_9138330
700 1 _aBhattacharya, Sanjoy K.
_c(Professor of ophthalmology),
_eeditor literario
_984858
700 1 _aNicholas, Anthony P.,
_eeditor literario
_984857
700 1 _aThompson, Paul R.,
_eeditor literario
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-58244-3
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
988 _aEBOOK, asignarmaterias, EBSPRINGER_2017
998 _b02/2018
_dz
_e-
_zSI
999 _c96555
_d96555
_x1